ArticleBMC musculoskeletal disorders2026
Injectable rhBMP-2-loaded calcium phosphate cement and chitosan composite hydrogel for the repair of osteoporotic bone defects.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Porcelain-clay-inspired microsphere hydrogel bioink facilitates bone regeneration via immune-osteogenic regulation.Bioactive materials · 2027Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegeneration of osteoporotic bone defects is a major clinical challenge due to impaired osteogenic activity and high infection risks. We developed an injectable rhBMP-2-loaded calcium phosphate cement (CPC) and chitosan (CH) composite hydrogel (rhBMP-2/CPC@CH) to evaluate its therapeutic efficacy for repairing osteoporotic bone defects.
methodsThe rhBMP-2/CPC@CH hydrogel was synthesized and characterized for its physicochemical properties and enzymatic degradation. Its osteogenic potential was assessed using BMSCs. An OVX-induced rat cranial defect model was established to evaluate in vivo bone repair via Micro-CT and histological analysis. Antibacterial activity and effects on wound healing were also investigated.
resultsThe rhBMP-2/CPC@CH hydrogel exhibited excellent injectability, self-healing, and enzymatic degradation properties with a uniform elemental distribution. The hydrogel significantly promoted the osteogenic differentiation of BMSCs, as evidenced by increased ALP activity and mineralized nodule formation. In the OVX-induced rat model, Micro-CT and histological analysis demonstrated that the hydrogel significantly increased bone mineral density and bone volume fraction, leading to dense new bone formation. Furthermore, the hydrogel effectively inhibited the growth of S. aureus and E. coli without adverse effects on wound healing, establishing a protected regenerative microenvironment.
conclusionsThe rhBMP-2/CPC@CH hydrogel accelerates the repair of osteoporotic bone defects by providing an osteoinductive microenvironment and intrinsic antibacterial defense, representing a promising minimally invasive strategy for clinical bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.